Mechanism of action of a nanomolar potent, allosteric antagonist of the thyroid-stimulating hormone receptor. 2012

Chris J van Koppen, and Marcel E de Gooyer, and Willem-Jan Karstens, and Ralf Plate, and Paolo G M Conti, and Tanja A E van Achterberg, and Monique G A van Amstel, and Jolanda H G M Brands, and Jesse Wat, and Rob J W Berg, and J Robert D Lane, and Andre M M Miltenburg, and C Marco Timmers
Department of Molecular Pharmacology, Medicinal Chemistry Early Clinical Research, Merck Research Laboratories, the Netherlands. chris.vankoppen@online.de

OBJECTIVE Graves' disease (GD) is an autoimmune disease in which the thyroid is overactive, producing excessive amounts of thyroid hormones, caused by thyroid-stimulating hormone (TSH) receptor-stimulating immunoglobulins (TSIs). Many GD patients also suffer from thyroid eye disease (Graves' ophthalmopathy or GO), as TSIs also activate TSH receptors in orbital tissue. We recently developed low molecular weight (LMW) TSH receptor antagonists as a novel therapeutic strategy for the treatment of GD and GO. Here, we determined the molecular pharmacology of a prototypic, nanomolar potent LMW TSH receptor antagonist, Org 274179-0. METHODS Using CHO cells heterogeneously expressing human TSH receptors and rat FRTL-5 cells endogenously expressing rat TSH receptors, we determined the potency and efficacy of Org 274179-0 at antagonizing TSH- and TSI-induced TSH receptor signalling and its cross-reactivity at related follicle-stimulating hormone and luteinizing hormone receptors. We analysed the allosteric mode of interaction of Org 274179-0 and determined whether it is an inverse agonist at five naturally occurring, constitutively active TSH receptor mutants. RESULTS Nanomolar concentrations of Org 274179-0 completely inhibited TSH (and TSI)-mediated TSH receptor activation with little effect on the potency of TSH, in accordance with an allosteric mechanism of action. Conversely, increasing levels of TSH receptor stimulation only marginally reduced the antagonist potency of Org 274179-0. Org 274179-0 fully blocked the increased basal activity of all the constitutively active TSH receptor mutants tested with nanomolar potencies. CONCLUSIONS Nanomolar potent TSH receptor antagonists like Org 274179-0 have therapeutic potential for the treatment of GD and GO.

UI MeSH Term Description Entries
D008970 Molecular Weight The sum of the weight of all the atoms in a molecule. Molecular Weights,Weight, Molecular,Weights, Molecular
D011989 Receptors, Thyrotropin Cell surface proteins that bind pituitary THYROTROPIN (also named thyroid stimulating hormone or TSH) and trigger intracellular changes of the target cells. TSH receptors are present in the nervous system and on target cells in the thyroid gland. Autoantibodies to TSH receptors are implicated in thyroid diseases such as GRAVES DISEASE and Hashimoto disease (THYROIDITIS, AUTOIMMUNE). Receptors, Thyroid Stimulating Hormone,TSH Receptors,Thyroid Stimulating Hormone Receptors,Thyrotropin Receptors,LATS Receptors,Receptor, LATS Immunoglobulins,Receptors, LATS,Receptors, Long-Acting Thyroid Stimulator,Receptors, TSH,TSH Receptor,Thyroid Stimulating Hormone Receptor,Thyrotropin Receptor,Receptor, TSH,Receptor, Thyrotropin,Receptors, Long Acting Thyroid Stimulator
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D003412 Cricetulus A genus of the family Muridae consisting of eleven species. C. migratorius, the grey or Armenian hamster, and C. griseus, the Chinese hamster, are the two species used in biomedical research. Hamsters, Armenian,Hamsters, Chinese,Hamsters, Grey,Armenian Hamster,Armenian Hamsters,Chinese Hamster,Chinese Hamsters,Grey Hamster,Grey Hamsters,Hamster, Armenian,Hamster, Chinese,Hamster, Grey
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D006111 Graves Disease A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy). Basedow's Disease,Exophthalmic Goiter,Goiter, Exophthalmic,Graves' Disease,Basedow Disease,Hyperthyroidism, Autoimmune,Basedows Disease,Disease, Basedow,Disease, Basedow's,Disease, Graves,Disease, Graves',Exophthalmic Goiters,Goiters, Exophthalmic
D006224 Cricetinae A subfamily in the family MURIDAE, comprising the hamsters. Four of the more common genera are Cricetus, CRICETULUS; MESOCRICETUS; and PHODOPUS. Cricetus,Hamsters,Hamster
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000262 Adenylyl Cyclases Enzymes of the lyase class that catalyze the formation of CYCLIC AMP and pyrophosphate from ATP. Adenyl Cyclase,Adenylate Cyclase,3',5'-cyclic AMP Synthetase,Adenylyl Cyclase,3',5' cyclic AMP Synthetase,AMP Synthetase, 3',5'-cyclic,Cyclase, Adenyl,Cyclase, Adenylate,Cyclase, Adenylyl,Cyclases, Adenylyl,Synthetase, 3',5'-cyclic AMP
D000634 Aminoquinolines Quinolines substituted in any position by one or more amino groups.

Related Publications

Chris J van Koppen, and Marcel E de Gooyer, and Willem-Jan Karstens, and Ralf Plate, and Paolo G M Conti, and Tanja A E van Achterberg, and Monique G A van Amstel, and Jolanda H G M Brands, and Jesse Wat, and Rob J W Berg, and J Robert D Lane, and Andre M M Miltenburg, and C Marco Timmers
March 1968, Metabolism: clinical and experimental,
Chris J van Koppen, and Marcel E de Gooyer, and Willem-Jan Karstens, and Ralf Plate, and Paolo G M Conti, and Tanja A E van Achterberg, and Monique G A van Amstel, and Jolanda H G M Brands, and Jesse Wat, and Rob J W Berg, and J Robert D Lane, and Andre M M Miltenburg, and C Marco Timmers
January 2023, Nature communications,
Chris J van Koppen, and Marcel E de Gooyer, and Willem-Jan Karstens, and Ralf Plate, and Paolo G M Conti, and Tanja A E van Achterberg, and Monique G A van Amstel, and Jolanda H G M Brands, and Jesse Wat, and Rob J W Berg, and J Robert D Lane, and Andre M M Miltenburg, and C Marco Timmers
October 2019, iScience,
Chris J van Koppen, and Marcel E de Gooyer, and Willem-Jan Karstens, and Ralf Plate, and Paolo G M Conti, and Tanja A E van Achterberg, and Monique G A van Amstel, and Jolanda H G M Brands, and Jesse Wat, and Rob J W Berg, and J Robert D Lane, and Andre M M Miltenburg, and C Marco Timmers
January 1984, The Journal of endocrinology,
Chris J van Koppen, and Marcel E de Gooyer, and Willem-Jan Karstens, and Ralf Plate, and Paolo G M Conti, and Tanja A E van Achterberg, and Monique G A van Amstel, and Jolanda H G M Brands, and Jesse Wat, and Rob J W Berg, and J Robert D Lane, and Andre M M Miltenburg, and C Marco Timmers
July 2018, Endocrinology,
Chris J van Koppen, and Marcel E de Gooyer, and Willem-Jan Karstens, and Ralf Plate, and Paolo G M Conti, and Tanja A E van Achterberg, and Monique G A van Amstel, and Jolanda H G M Brands, and Jesse Wat, and Rob J W Berg, and J Robert D Lane, and Andre M M Miltenburg, and C Marco Timmers
June 2009, Endocrinology and metabolism clinics of North America,
Chris J van Koppen, and Marcel E de Gooyer, and Willem-Jan Karstens, and Ralf Plate, and Paolo G M Conti, and Tanja A E van Achterberg, and Monique G A van Amstel, and Jolanda H G M Brands, and Jesse Wat, and Rob J W Berg, and J Robert D Lane, and Andre M M Miltenburg, and C Marco Timmers
September 1995, Biochemistry,
Chris J van Koppen, and Marcel E de Gooyer, and Willem-Jan Karstens, and Ralf Plate, and Paolo G M Conti, and Tanja A E van Achterberg, and Monique G A van Amstel, and Jolanda H G M Brands, and Jesse Wat, and Rob J W Berg, and J Robert D Lane, and Andre M M Miltenburg, and C Marco Timmers
February 2017, Molecular imaging and radionuclide therapy,
Chris J van Koppen, and Marcel E de Gooyer, and Willem-Jan Karstens, and Ralf Plate, and Paolo G M Conti, and Tanja A E van Achterberg, and Monique G A van Amstel, and Jolanda H G M Brands, and Jesse Wat, and Rob J W Berg, and J Robert D Lane, and Andre M M Miltenburg, and C Marco Timmers
April 2002, Physiological reviews,
Chris J van Koppen, and Marcel E de Gooyer, and Willem-Jan Karstens, and Ralf Plate, and Paolo G M Conti, and Tanja A E van Achterberg, and Monique G A van Amstel, and Jolanda H G M Brands, and Jesse Wat, and Rob J W Berg, and J Robert D Lane, and Andre M M Miltenburg, and C Marco Timmers
November 1974, The Journal of endocrinology,
Copied contents to your clipboard!